This inspiring article from Pfizer follows a patient named Eric through his clinical trial journey. For those looking to learn more about the clinical trial process, this is a great resource. “From the thousands of patients who volunteer each year to the scientists, clinicians, and principal investigators (PIs), each individual who contributes to a trial helps to bring about life-changing treatments and advances our knowledge of diseases.” #ClinicalTrials #Patients #Safety #Discovery https://lnkd.in/eUQEb2bn
Prevail InfoWorks’ Post
More Relevant Posts
-
Big Bucks: Adcendo’s $1 Billion Cancer Bet on ADC Technology Exciting news coming from Denmark's Adcendo: The biotech company has struck a major deal worth up to $1 billion with Multitude Therapeutics for the ex-China rights to ADCE-T02, a promising preclinical antibody-drug conjugate (ADC). The first-in-class ADC is set to begin a phase 1 trial in Australia later this year, with plans for a U.S. study soon after. This innovative ADC, featuring a topoisomerase I inhibitor-based linker/payload, is designed to target solid tumors with precision, offering hope for improved safety profiles and better outcomes for cancer patients. Do you know many phase 1 deals done for a billion dollars? “We are highly impressed by the deep science behind Multitude Therapeutics’ linker/payload platforms and are delighted about our licensing agreement on ADCE-T02, which perfectly complements our existing unique first-in-class ADC pipeline and allows Adcendo to become a clinical-stage biotech company in Q4 2024,” says Michael Pehl, Adcendo CEO. Feel free to check out the article linked in the comments below. #BiotechInnovation #CancerResearch #ADCTechnology #PharmaDeals #OncologyBreakthrough #PrecisionMedicine #LifeSciences #ClinicalTrials #Biotechnology #PharmaPartnerships #HealthcareInnovation #FutureOfMedicine #Adcendo #MultitudeTherapeutics
Denmark's Adcendo signs $1B biobuck deal for Multitude’s anti-TF ADC
fiercebiotech.com
To view or add a comment, sign in
-
Pathalys Pharma Secures $105M Series B to Drive Kidney Disease Drug to FDA Approval Pathalys Pharma investors have made a bold move in the fight against kidney disease, providing $105 million in a Series B funding round to push Pathalys’s lead drug, upacicalcet, toward FDA approval. This innovative calcimimetic, already a success in Japan, could revolutionize the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients. With these new funds, Pathalys is poised to complete two critical Phase 3 trials and ramp up pre-approval preparations. This milestone reflects strong investor confidence in Pathalys' mission to deliver cutting-edge therapies for end-stage kidney disease. Share your thoughts on this significant funding milestone and its potential impact on kidney disease treatments. Read more in the article in the comment section. “Since our inception, Pathalys has made significant strides toward our goal of delivering a best-in-class treatment for those with end-stage kidney disease (ESKD), including the near completion of two phase 3 clinical trials for upacicalcet,” Pathalys CEO Neal Fowler said in the Aug. 20 release. #KidneyHealth #Biotech #PharmaNews #ClinicalResearch #HealthcareFunding #MedicalAdvancements #FDAApproval #ChronicKidneyDisease #HealthcareInvestments #LifeSciences
Pathalys raises $105M series B to prepare Japan-approved kidney disease drug for FDA
fiercebiotech.com
To view or add a comment, sign in
-
Milestone Achieved: FDA Greenlights Gilead's Newly Poised “Livdelzi” to Make a Big Impact Perhaps you caught our previous LinkedIn post that was shared by us 2 months ago. As it happens, what we’ve been hoping for has come to fruition. Gilead Sciences has now received FDA approval for Livdelzi (seladelpar), a new treatment for a rare liver disease known as primary biliary cholangitis. This approval is crucial for patients who can’t tolerate or don't respond well to existing treatments. Livdelzi is now available alone or in combination with other therapies and has strong potential in the market. How will Livdelzi's FDA approval reshape the options available for patients with primary biliary cholangitis? RBC Capital Markets analyst Brian Abrahams noted that Livdelzi's "cleaner label and itch relief benefits" are likely to give it a competitive advantage. Feel free to check out the article linked in the comments below. #Livdelzi #FDAApproval #PrimaryBiliaryCholangitis #GileadSciences #Biotech #Pharma #HealthcareInnovation #LiverDisease #NewTreatment #CymaBayTherapeutics #DrugDevelopment #MarketImpact #MedicalBreakthrough
FDA clears Gilead drug acquired in $4.3B buyout
biopharmadive.com
To view or add a comment, sign in
-
Halda’s $126M Power Move: Revolutionizing Cancer Treatment with ‘Hold and Kill’ Technology Innovative strides in cancer treatment are on the horizon. Halda Therapeutics has secured a substantial $126 million in Series B funding to propel its pioneering RIPTAC program into clinical trials. RIPTAC, which stands for Regulated Induced Proximity Targeting Chimeras, represents a novel “hold and kill” mechanism that promises to target and eliminate cancer cells while sparing healthy tissue. This funding will fuel the advancement of HLD-0915, set to enter a Phase 1 trial for metastatic, castration-resistant prostate cancer in the first half of next year. Halda’s breakthrough approach could potentially overcome drug resistance—a significant hurdle in current cancer therapies. This “oral, selective, and widely applicable cancer cell-killing mechanism … is designed to overcome drug resistance, which is a major shortcoming of many current standard of care cancer treatments,” Halda Chief Scientific Officer Kat Kayser-Bricker, Ph.D., explained in an Aug. 12 release. The future of oncology is looking brighter with each step forward. How do you think Halda’s ‘hold and kill’ approach could reshape the future of cancer treatment? Read more in the article in the comment section. #Oncology #Biotech #CancerResearch #Innovation #Healthcare #VentureCapital
Halda raises $126M to advance 'hold and kill' solid tumor drugs into the clinic
fiercebiotech.com
To view or add a comment, sign in
-
$700M Deal: Can Merck’s CN201 Disrupt the Oncology and Autoimmune Markets? Merck is stepping into the blood cancer market with a $700 million upfront deal to acquire global rights to Curon Biopharmaceutical’s CD3xCD19 bispecific candidate, CN201. This move positions Merck as a strong competitor against Amgen and AstraZeneca in oncology and Cullinan Therapeutics in autoimmune diseases. Early clinical data shows promising results in non-Hodgkin lymphoma and acute lymphoblastic leukemia, with a focus on reducing cytokine release syndrome. Merck is committed to advancing CN201 in B-cell malignancies and exploring its potential in autoimmune conditions. How do you see Merck’s acquisition of CN201 impacting the competitive landscape in both oncology and autoimmune disease treatment? Did you find this move on Merck’s part surprising? “Autoimmune diseases are on Merck’s roadmap for CN201. Interest in targeting CD19 has intensified in recent years as researchers have published data on a CAR-T candidate in lupus,” says Fierce Biotech writer Nick Paul Taylor. Read more in the article in the comment section. #Acquisition #Oncology #Autoimmune #Biotech #Pharma #CancerResearch #BloodCancer #HealthcareInnovation #PharmaDeals #ClinicalTrials #CN201 #MedicalResearch #CD19 #HealthcareIndustry
Merck pays $700M for bispecific, spying autoimmune opening and chance to challenge Amgen in cancer
fiercebiotech.com
To view or add a comment, sign in
-
Sangamo and Genentech Forge $50M Partnership to Tackle Alzheimer’s Sangamo Therapeutics, Inc. has secured a significant lifeline through a $50M upfront deal with Roche's Genentech, focusing on innovative genomic medicines for neurodegenerative diseases. This global licensing agreement grants Genentech exclusive rights to Sangamo’s proprietary zinc finger repressors, targeting the tau gene associated with Alzheimer’s disease and another undisclosed neurology target. What could that other “undisclosed” neurology target be? Key Highlights: Exclusive Rights: Genentech now holds exclusive rights to Sangamo’s STAC-BBB technology, which has shown exceptional blood-brain barrier penetration and brain transduction in animal models. Collaborative Effort: Sangamo will handle technology transfer and preclinical activities, while Genentech will spearhead clinical development, regulatory efforts, manufacturing, and global commercialization. Financial Boost: The deal includes $50M upfront and potential milestone payments up to $1.9 billion, plus tiered royalties. This partnership highlights the critical role of innovative collaborations in advancing treatments for neurodegenerative diseases. Do you think this deal might have been clinched during the AAIC conference in Philadelphia last week? Tell us what you think. “Through groundbreaking research and partnerships with companies such as Sangamo, we are committed to pursuing important breakthroughs in both early diagnosis and treatment.” Boris L. Zaïtra, head of Roche’s corporate business development arm, said in an Aug. 6 release. Read more in the article in the comment section. #Biotechnology #GeneTherapy #NeurodegenerativeDiseases #SangamoTherapeutics #Roche #Genentech #Innovation #Healthcare #LifeSciences
Sangamo secures $50M upfront in neurodegenerative pact with Roche's Genentech
fiercebiotech.com
To view or add a comment, sign in
-
Biotech Shake-Up: Otsuka's $800M Acquisition of Jnana Sparks Excitement for PKU Innovation Acquisition News: Otsuka Pharmaceutical Co., Ltd. is set to acquire Jnana Therapeutics for $800 million, aiming to advance their oral phenylketonuria (PKU) drug JNT-517. The deal, closing in Q3, also includes up to $325 million in milestone payments. Central to the deal is JNT-517, an allosteric small-molecule inhibitor targeting SLC6A19, which regulates amino acid reabsorption in the kidney. This drug has successfully completed a phase 1b/2 trial, proving its tolerability. Otsuka envisions JNT-517 as a potential first-in-class oral treatment for PKU. What do you think will be the broader impact of Otsuka's acquisition of Jnana Therapeutics and the development of JNT-517? As Otsuka bolsters its pipeline with this new acquisition, will this bring any “buzz” to this therapeutic area? “I am gratified that Otsuka has entered into an agreement with Jnana,” says Makoto Inoue, Otsuka president and representative director. Read more in the article in the comment below. #BiotechNews #PharmaDeals #PKU #Phenylketonuria #OtsukaPharmaceuticals #JnanaTherapeutics #DrugDiscovery #ClinicalTrials #HealthcareInnovation #PharmaAcquisition #BiotechInnovation #RareDiseases #GlobalExpansion #PharmaceuticalIndustry #LifeSciences
Otsuka pays $800M for Jnana Therapeutics and its clinical-stage PKU drug
fiercebiotech.com
To view or add a comment, sign in
-
Unlocking the Brain: How a Parasitic Hijacker is Revolutionizing Drug Delivery! Researchers have genetically engineered the parasite Toxoplasma gondii to deliver drugs across the blood-brain barrier, potentially revolutionizing the treatment of neurological diseases. Shahar Bracha, Ph.D., from Massachusetts Institute of Technology, led the study published in Nature Microbiology, demonstrating how this cunning parasite can be repurposed for good. This breakthrough highlights the power of innovation. Exciting times ahead for neuroscience - what are some other applications do you know of that may be as bizarre, unimaginable, but also as interesting and exciting as this? The blood-brain barrier is a protective shield that restricts which molecules can enter our brain. “[This] is very important to protect the brain, but also it makes it really hard when you do want to deliver specific things to the brain,” Bracha says. Bracha had later discovered research detailing how T. gondii can cross the human blood-brain barrier and infect neurons, potentially by hijacking immune cells. "The more we heard about it, the more we realized it can do exactly everything we need in order to enable drug delivery to the brain.” Read more in the article in the comment below. #Neuroscience #DrugDelivery #Biotechnology #MedicalInnovation #NeurologicalDiseases #ToxoplasmaGondii #BrainResearch #BloodBrainBarrier #MITResearch #NatureMicrobiology #BiomedicalResearch #InnovativeTherapies #GeneticEngineering #HealthcareInnovation #ParasiteTherapy
Researchers engineer brain-infecting parasite into living drug delivery system
fiercebiotech.com
To view or add a comment, sign in
-
New Hope in the Vital Research for a Glioblastoma Treatment TVAX Biomedical, Inc. Biomedical announced the opening of enrollment for patients across the US in their innovative clinical study targeting newly diagnosed MGMT (O6-Methylguanine-DNA methyltransferase) unmethylated glioblastoma. Whether it is 'methylated' or 'unmethylated' indicates how effectively the tumor cells can repair the damage inflicted on them by certain chemotherapy drugs. By using the patients' own cancer cells collected from the surgery, they create a personalized vaccine that generates a robust immune response, significantly increasing cancer neoantigen-specific effector T cell precursors. Their dedicated team is passionate about advancing research and improving outcomes for glioblastoma patients. They are making important strides toward a more effective therapy and a brighter future. Follow them on this journey and stay tuned for more exciting updates. Learn more from their website: https://lnkd.in/gueyfQw3 #Glioblastoma #ClinicalStudy #Immunotherapy #Healthcare #Biotech #CancerResearch #PatientEnrollment #MedicalAdvancements #Innovation #Hope
TVAX Biomedical, Inc.
tvaxbiomedical.com
To view or add a comment, sign in
This is a great piece